Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT00025467 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

NIH

Sponsor class

Conditions

Endometrial Adenoacanthoma
Endometrial Adenocarcinoma
Endometrial Adenosquamous Cell Carcinoma
Endometrial Clear Cell Carcinoma
Endometrial Papillary Serous Carcinoma
Recurrent Endometrial Carcinoma

Interventions

DRUG: thalidomide
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)